COVISHIELD: Enrollment of clinical trials
--Must See--

Whatsapp Job Assistance Program

COVISHIELD: Enrollment of phase 3 clinical trials completed by ICMR and SII

ICMR and Serum Institute of India (SII), Pune, has declared that, as of 31 October 2020, the enrolment procedure of phase 3 clinical trials for COVISHIELD has been concluded. This vaccine was originally developed by Oxford University/Astra Zeneca trial. It is also under trials in the United Kingdom, South Africa, Brazil, and the US. SII collaborating with ICMR is carrying out phase 2 and 3 clinical trials of this vaccine at 15 distinct centers throughout the nation.

1600 individuals will be involved in phase 3 human trials of COVISHIELD.

The clinical trial site costs are funded by the ICMR. At the same time, SII is funding all the various other costs for the trials.

Additionally, SII has produced 40 million dosages of the vaccines under the at-risk production and stockpiling permission from the DCGI.

SII stated that the encouraging outcomes of the trials thus far assure that this vaccine could be a genuine solution to the fatal pandemic.

Serum Institute of India and the Indian Council of Medical Research have also partnered to obtain Novavax’s COVID-19 vaccine prospect of the US to India. The vaccine is called COVOVAX

and is currently being analyzed in South Africa and the United Kingdom. Trials will soon commence in the U.S also.

Phase 3 trials of the vaccine will also be tested in India by SII. But, no specific date has been provided.

Presently, India plays a notable role internationally in vaccine development and production, stated Dr. Balram Bhargava, Director General of ICMR. With the most advanced technology and well-equipped amenities, Serum Institute of India has consistently proved its research and manufacturing excellence.

He further stated that the collaboration contributes to lending their competence and support to reinforce their battle against COVID-19.


COVISHIELD: Enrollment of phase 3 clinical trials completed by ICMR and SII